Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Du bruger tilsyneladende en bredere skærm. Vil du gerne give denne side en bredere visningsoplevelse?

Ascelia Pharma - Presentation of Q3 2023

Af HC Andersen Capital
Ascelia Pharma

Meet and ask questions CEO Magnus Corfitzen from Ascelia Pharma on 9 November at 2.30PM CET.

The topic for this event is the Q3 report and major events during the quarter. It’s been a very busy quarter for Ascelia Pharma with major news flow on the Sparkle study.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 3.11 PM 18 October 2023.

Seneste videoer

Arjo, Audiocast, Q4'25
30.01.2026, 13.00 Arjo
AKTIER MED FRIIS - UGE 5 2026
30.01.2026, 12.00
Midsona, Audiocast, Q4'25
30.01.2026, 11.00 Midsona
Elisa, Webcast, Q4'25
30.01.2026, 11.00 Elisa
Beijer Ref, Audiocast, Q4'25
30.01.2026, 10.00 Beijer Ref
Vis alle videoer
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.